{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:10:39Z","timestamp":1788865839033,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017568","name":"Rokitan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.drudis.2021.03.018","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T03:57:09Z","timestamp":1616817429000},"page":"1591-1601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-5533","authenticated-orcid":false,"given":"Johann","family":"Sellner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald H.","family":"Sitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus S.","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.03.018_b0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.drudis.2021.03.018_b0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"issue":"Pt 5","key":"10.1016\/j.drudis.2021.03.018_b0015","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2021.03.018_b0020","first-page":"218","article-title":"Distribution of aquaporins 1 and 4 in the central nervous system","volume":"45","author":"Rosu","year":"2019","journal-title":"Curr Health Sci J"},{"key":"10.1016\/j.drudis.2021.03.018_b0025","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.drudis.2021.03.018_b0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2021.03.018_b0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaut.2009.09.013","article-title":"The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes","volume":"34","author":"Sellner","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2021.03.018_b0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.drudis.2021.03.018_b0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.drudis.2021.03.018_b0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2021.03.018_b0060","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2021.03.018_b0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-015-0240-9","article-title":"The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations","volume":"12","author":"Kowarik","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.drudis.2021.03.018_b0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2021.03.018_b0075","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2021.03.018_b0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14737175.2020.1757434","article-title":"Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options","volume":"20","author":"Rosso","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.drudis.2021.03.018_b0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2021.03.018_b0090","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.drudis.2021.03.018_b0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2021.03.018_b0100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/BOR.0000000000000603","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"31","author":"Romeo","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.drudis.2021.03.018_b0105","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41409-020-0810-z","article-title":"Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis","volume":"55","author":"Zhang","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.drudis.2021.03.018_b0110","unstructured":"FDA (2019) Soliris\u00ae (Eculizumab) Concentrated Solution for Intravenous Infusion, FDA"},{"key":"10.1016\/j.drudis.2021.03.018_b0115","series-title":"Soliris 300 mg Concentrate","author":"EMA","year":"2019"},{"key":"10.1016\/j.drudis.2021.03.018_b0120","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled Phase II\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.03.018_b0125","unstructured":"FDA (2020) UPLIZNATM (inebilizumab-cdon) Injection, for Intravenous Use, FDA"},{"key":"10.1016\/j.drudis.2021.03.018_b0130","unstructured":"FDA (2020) ENSPRYNG\u2122 (satralizumab-mwge) Injection, for Subcutaneous Use, FDA"},{"key":"10.1016\/j.drudis.2021.03.018_b0135","unstructured":"EMA (2020) Satralizumab Humanised Anti-IL-6 Receptor Monoclonal Antibody for the Treatment of Neuromyelitis Optica Spectrum Disorders, EMA"},{"key":"10.1016\/j.drudis.2021.03.018_b0140","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL\u20136 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2021.03.018_b0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2021.03.018_b0150","article-title":"Physiological effects of modulating the interleukin-6 axis","volume":"57","author":"Schett","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.drudis.2021.03.018_b0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.drudis.2021.03.018_b0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000505099","article-title":"Interleukin-6: a masterplayer in the cytokine network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.drudis.2021.03.018_b0165","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble Interleukin 6 receptor: generation and role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.drudis.2021.03.018_b0170","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2021.03.018_b0175","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1084\/jem.191.6.915","article-title":"Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling","volume":"191","author":"Teague","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2021.03.018_b0180","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.4049\/jimmunol.173.8.5290","article-title":"Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6\/soluble IL-6 receptor trans-signaling","volume":"173","author":"Curnow","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0185","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/jcp.25575","article-title":"Endothelial STAT3 activation increases vascular leakage through downregulating tight junction proteins: implications for diabetic retinopathy","volume":"232","author":"Yun","year":"2017","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2021.03.018_b0190","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000026339","article-title":"Role of the brain in interleukin-6 modulation","volume":"5","author":"Terreni","year":"1998","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.drudis.2021.03.018_b0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0200","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.03.018_b0205","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0210","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/blood-2011-11-392985","article-title":"Functional STAT3 deficiency compromises the generation of human T follicular helper cells","volume":"119","author":"Ma","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.03.018_b0215","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","article-title":"IL-6\/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells","volume":"141","author":"Okada","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0220","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.0b013e3181c1deb9","article-title":"Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis","volume":"73","author":"Yanagawa","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2021.03.018_b0225","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.drudis.2021.03.018_b0230","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2021.03.018_b0235","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","author":"Icoz","year":"2010","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.drudis.2021.03.018_b0240","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","article-title":"Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica","volume":"19","author":"Wang","year":"2012","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.drudis.2021.03.018_b0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks","volume":"421","author":"Uzawa","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.drudis.2021.03.018_b0250","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","article-title":"CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse","volume":"83","author":"Uzawa","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.drudis.2021.03.018_b0255","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000494976","article-title":"Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6","volume":"25","author":"Wei","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.drudis.2021.03.018_b0260","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1352458516672015","article-title":"Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood-brain barrier disruption","volume":"23","author":"Uchida","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2021.03.018_b0265","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood\u2013brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.drudis.2021.03.018_b0270","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.drudis.2021.03.018_b0275","doi-asserted-by":"crossref","unstructured":"Lauenstein, A.S., et al. (2014) Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep 2014, bcr2013202939.","DOI":"10.1136\/bcr-2013-202939"},{"key":"10.1016\/j.drudis.2021.03.018_b0280","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2017.11.041","article-title":"Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Masuda","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.drudis.2021.03.018_b0285","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMp1715349","article-title":"The myth of the milkmaid","volume":"378","author":"Boylston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.03.018_b0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1258\/jmb.2010.010009","article-title":"Birth of the science of immunology","volume":"18","author":"Schmalstieg","year":"2010","journal-title":"J Med Biogr"},{"key":"10.1016\/j.drudis.2021.03.018_b0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.03.018_b0300","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nbt0708-743","article-title":"(Re)defining biopharmaceutical","volume":"26","author":"Rader","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2021.03.018_b0305","doi-asserted-by":"crossref","first-page":"e00035","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2021.03.018_b0310","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0315","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.cellbio.12.1.181","article-title":"Fc receptors and their interactions with immunoglobulins","volume":"12","author":"Raghavan","year":"1996","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.drudis.2021.03.018_b0320","doi-asserted-by":"crossref","unstructured":"Napodano, C., et al. (2020) Immunological role of IgG subclasses. Immunol Invest. Published online June 11, 2020. http:\/\/dx.doi.org\/10.1080\/08820139.2020.1775643.","DOI":"10.1080\/08820139.2020.1775643"},{"key":"10.1016\/j.drudis.2021.03.018_b0325","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/19420862.2015.1054585","article-title":"A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life","volume":"7","author":"Souders","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2021.03.018_b0330","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cell.2019.05.044","article-title":"Fc glycan-mediated regulation of placental antibody transfer","volume":"178","author":"Jennewein","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.03.018_b0335","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cell.2019.05.046","article-title":"Fc characteristics mediate selective placental transfer of IgG in HIV-infected women","volume":"178","author":"Martinez","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.03.018_b0340","doi-asserted-by":"crossref","first-page":"12943","DOI":"10.1073\/pnas.2004325117","article-title":"FcRn, but not FcgammaRs, drives maternal-fetal transplacental transport of human IgG antibodies","volume":"117","author":"Borghi","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2021.03.018_b0345","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0167-5699(97)01172-9","article-title":"FcRn: the MHC class I-related receptor that is more than an IgG transporter","volume":"18","author":"Ghetie","year":"1997","journal-title":"Immunol Today"},{"key":"10.1016\/j.drudis.2021.03.018_b0350","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1038\/s41598-019-40731-2","article-title":"Reduced FcRn-mediated transcytosis of IgG2 due to a missing glycine in its lower hinge","volume":"9","author":"Stapleton","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2021.03.018_b0355","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0360","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cmdc.201600374","article-title":"Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation","volume":"11","author":"van Witteloostuijn","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2021.03.018_b0365","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3389\/fimmu.2020.00810","article-title":"Relevance of the materno-fetal interface for the induction of antigen-specific immune tolerance","volume":"11","author":"Mimoun","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0370","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.drudis.2021.03.018_b0375","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0380","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0385","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0390","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/1061186X.2013.875030","article-title":"Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering","volume":"22","author":"Wang","year":"2014","journal-title":"J Drug Target"},{"issue":"Suppl. 3","key":"10.1016\/j.drudis.2021.03.018_b0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-3002-0","article-title":"Advances in the understanding of the mechanism of action of IVIg","volume":"255","author":"Hartung","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.drudis.2021.03.018_b0400","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2021.03.018_b0405","unstructured":"Neurology Live (2020) Efgartigimod Meets Primary End Point in Myasthenia Gravis, Neurology Live."},{"key":"10.1016\/j.drudis.2021.03.018_b0410","unstructured":"A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis. clinicaltrials.gov\/ct2\/show\/NCT03971422 [Accessed March 18, 2021]."},{"key":"10.1016\/j.drudis.2021.03.018_b0415","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/imt-2016-0067","article-title":"Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications","volume":"8","author":"Levy","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.drudis.2021.03.018_b0420","unstructured":"VRC 609: a phase I, open-label, dose-escalation study of the safety and pharmacokinetics of a human monoclonal antibody, VRC-HIVMAB091-00-AB (N6LS), administered intravenously or subcutaneously with or without recombinant human hyaluronidase PH20 (rHuPH20) to healthy adults. clinicaltrials.gov\/ct2\/show\/NCT03538626 [Accessed March 18, 2021]."},{"key":"10.1016\/j.drudis.2021.03.018_b0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2021.03.018_b0430","first-page":"1098","article-title":"Extending human IgG half-life using structure-guided design","volume":"10","author":"Booth","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2021.03.018_b0435","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","article-title":"Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn","volume":"89","author":"Israel","year":"1996","journal-title":"Immunology"},{"key":"10.1016\/j.drudis.2021.03.018_b0440","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0445","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymeth.2013.07.005","article-title":"Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies","volume":"65","author":"Proetzel","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2021.03.018_b0450","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2021.03.018_b0455","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/protein\/gzq009","article-title":"Reduced elimination of IgG antibodies by engineering the variable region","volume":"23","author":"Igawa","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.drudis.2021.03.018_b0460","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2021.03.018_b0465","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.03.018_b0470","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.03.018_b0475","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.drudis.2021.03.018_b0480","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/pbc.25595","article-title":"Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab","volume":"62","author":"Hellwig","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.drudis.2021.03.018_b0485","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","article-title":"Tocilizumab: a review of its use in the management of rheumatoid arthritis","volume":"69","author":"Oldfield","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2021.03.018_b0490","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3899\/jrheum.111439","article-title":"Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes, 2 components of the myeloid lineage","volume":"39","author":"Richez","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.drudis.2021.03.018_b0495","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00296-013-2778-0","article-title":"Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis","volume":"34","author":"Kasama","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.drudis.2021.03.018_b0500","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.03.018_b0505","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.drudis.2021.03.018_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102421","article-title":"A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders","volume":"45","author":"Xie","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.drudis.2021.03.018_b0515","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/1570159X18666200429010825","article-title":"Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy","volume":"19","author":"Lotan","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.drudis.2021.03.018_b0520","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.drudis.2021.03.018_b0525","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.03.018_b0530","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"24","key":"10.1016\/j.drudis.2021.03.018_b0535","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1073\/pnas.1019037108","article-title":"Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells","volume":"108","author":"Baker","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"10.1016\/j.drudis.2021.03.018_b0540","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1073\/pnas.0600548103","article-title":"Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene","volume":"103","author":"Wani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2021.03.018_b0545","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s10875-012-9768-y","article-title":"The immunologic functions of the neonatal Fc receptor for IgG","volume":"33","author":"Rath","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0550","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3389\/fimmu.2018.02259","article-title":"Lack of FcRn impairs natural killer cell development and functions in the tumor microenvironment","volume":"9","author":"Castaneda","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2021.03.018_b0555","unstructured":"FDA (2019) FDA Approves First Treatment for Neuromyelitis Optica Spectrum Disorder, a Rare Autoimmune Disease of the Central Nervous System, FDA."},{"key":"10.1016\/j.drudis.2021.03.018_b0560","unstructured":"EMA (2020) Soliris Product Information, EMA."},{"key":"10.1016\/j.drudis.2021.03.018_b0565","unstructured":"An efficacy and safety study of ravulizumab in adult participants with NMOSD. clinicaltrials.gov\/ct2\/show\/NCT04201262 [Accessed March 18, 2021]."},{"key":"10.1016\/j.drudis.2021.03.018_b0570","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2021.03.018_b0575","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621001549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621001549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:51:29Z","timestamp":1761223889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621001549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1359644621001549"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.03.018","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}